Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2014 Feb;28(1):13-25. doi: 10.1016/j.hoc.2013.10.009.

Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.

Author information

1
Seattle Genetics Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA. Electronic address: nokeley@seagen.com.

Abstract

The concept of using monoclonal antibodies for delivering drugs to cancer cells has been explored for decades, with early work surrounding nonspecific targets and drugs with low potencies. These studies underscored the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics, and conjugation methodology, in developing effective antibody drug conjugates with acceptable safety profiles. Brentuximab vedotin represents the culmination of much research and development activities in which many of these parameters were addressed. This article provides an overview of many studies that led to the development of this highly active antibody drug conjugate.

KEYWORDS:

Chemotherapeutic; Drug delivery; Immunotherapy; Monoclonal antibody; Targeting; Tumor

PMID:
24287064
DOI:
10.1016/j.hoc.2013.10.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center